insights_auto
Waarom is 2X1 gestegen 2,80%?
Meer informatiechevron_right
2X1:ETR
Abivax SA
€ 78,95
arrow_upward
+2,80%(+2,15) 1D
9 okt, 09:04:35 GMT+2 · EUR
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor 2X1 genereren…
Openen
€ 78,95
Hoog
€ 78,95
Laag
€ 78,95
Beursw.
6,91 mld.
Gem. vol.
1,81K
Volume
0,00
52 wk hoog
€ 137,40
52 wk laag
€ 60,85
WPA
€ -5,20
Aantal medewerkers
98
Openen
€ 78,95
Hoog
€ 78,95
Laag
€ 78,95
Beursw.
6,91 mld.
Gem. vol.
1,81K
Volume
0,00
52 wk hoog
€ 137,40
52 wk laag
€ 60,85
WPA
€ -5,20
Aantal medewerkers
98
Nieuwsartikelen
Van webbronnen en nieuwspartners
Ideal Investisseur
·
21 uur geleden
Abivax: stock plunges 1.5% and deepens its fall to 39% in three months
MarketBeat
·
2 dagen geleden
676,589 Shares in Abivax SA Sponsored ADR $ABVX Acquired by Two Seas Capital LP
Profiel
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Over Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Medewerkers98
Opgericht4 dec 2013
Hoofdkantoor-
Sector-
Websiteabivax.com